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ABSTRACT 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. It is characterized by 
hyperandrogenism, polycystic ovaries, and chronic anovulation along with insulin resistance, hyperinsulinemia, abdominal obesity, 
hypertension, and dyslipidemia as frequent metabolic traits (metabolic syndrome) that culminate in serious long-term consequences 
such as type 2 diabetes mellitus, endometrial hyperplasia, and coronary artery disease. It is one of the most common causes of 
anovulatory infertility. A complete understanding of the underlying Pathophysiology of PCOS is still lacking. Because of the 
heterogeneity of this disorder, there are most likely multiple underlying pathophysiologic mechanisms. Pathogenesis of PCOS is 
explaining as alteration in gonadotropin-releasing hormone secretion results in increased luteinizing hormone (LH) secretion. An 
alteration in insulin secretion and insulin action results in hyperinsulinemia and insulin resistance. A defect in androgen synthesis 
that results in increased ovarian androgen production.Treatment of PCOS include maintaining a normal endometrium, antagonizing 
the actions of androgens on target tissues, reducing insulin resistance (when present), and correcting anovulation. Women with 
polycystic ovary syndrome (PCOS) are at higher risk for several other health conditions as Insulin Resistance, Metabolic Syndrome, 
Type 2 Diabetes, Obesity, Heart Disease and High Blood Pressure (Cardiovascular Disease) 
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Polycystic ovary syndrome (PCOS) may clinically be 
manifested heterogeneous disorder that affects 5 to 10% 
of women of reproductive age or the most common 
endocrinopathy in young women of reproductive age as 
oligo-ovulation, biochemical or clinical 
hyperandrogenism in which other causes of androgen 
excess have been excluded  (hirsutism, male pattern 
balding, acne, acanthosis nigricans) and polycystic 
ovaries.
1   
Furthermore, the etiology of PCOS remains 
unclear; however, several studies have suggested that 
PCOS is an X-linked dominant condition. PCOS is 
associated with low level of follicle stimulating hormone 
(FSH) and high level of luteinizing hormone (LH) . In 
parallel, high level of LH triggers the secretion of 
estrogen, testosterone and dihydroepiandrosterone 
sulphate (DHES). This ultimately leads to development 
of cyst in the ovary.
2
 (PCOS) affects up to 10% of 
women of reproductive age, in which 
hyperandrogenism, enlarged cystic ovaries, and chronic 
anovulation often coexist with obesity, hypertension, 
and dyslipidemia as frequent metabolic traits (metabolic 
syndrome) that culminate in serious long-term 
consequences such as type 2 diabetes mellitus, 
endometrial hyperplasia, and coronary artery disease. 
Obesity in women with PCOS is rather high, ranging 
from 30%–60%, whereas hyperinsulinemia is present in 
more than 50% of patients with PCOS.
3  
Soni et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2018; 8(5):107-112           
ISSN: 2250-1177                                                                             [108]                                                                             CODEN (USA): JDDTAO 
There has been much debate over the years whether 
PCOS is a single disease or a combination of several 
disorders. However, is that PCOS is not only the most 
common cause of Anovulation and hirsuitism but is also 
associated with a characteristic metabolic disturbance 
(insulin resistance) that may have important implications 
for long-term health? Women with the polycystic ovary 
syndrome almost always have some aberration in 
gonadotropin secretion as compared with women who 
have normal menstrual cycles.
4   
Menstrual irregularity is the most common gynaecologic 
presentation of PCOS. Oligomenorrhea has been 
observed in 85 to 90% of women with PCOS, and as 
many as 30 to 40% of amenorrheic patients have PCOS. 
The prevalence of infertility, caused mainly by 
anovulation in PCOS women, varies between 35% and 
94%. South Asians with PCOS present at a younger age 
(26 ± 4 years vs. 30.1±5 years, respectively) and have 
oligomenorrhea commencing at a younger age in 
comparison with Caucasian women.  Hyperandrogenism 
is the key endocrine abnormality of PCOS, the 
prevalence of hirsutism in PCOS women ranging from 
17 to 83%. It is recognized that hirsutism is in part 
ethnically determined, being more common in women 
with dark skin.
1    
Table 1: Synonyms of PCOS 
Sr.No Name 
1 Polycystic ovary syndrome 
2 Polycystic ovary diseases  
3 Stein Leventhal Syndrome 
4 Polycystic ovarian Disease (PCOD) 
5 Sclerocystic ovarian hyperandrogenism 
6 





Figure 1: Ovary with PCOS 
SIGN & SYMPTOMS 
The main reason for PCOS still knows but the diseases 
can be finding out by sign & symptoms. These sign and 
symptoms can be helpful for the detection for PCOS as 
oligo-ovulation, hyperandrogenism (hirsutism, male 
pattern balding, acne, Acanthosis nigricans), obesity, 
hypertension, and dyslipidemia. 
 
Figure 2: Sign of PCOS 
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Oligoovulation:  
Oligoovulation is infrequent or irregular ovulation 
(usually defined as cycles of ≥36 days or <8 cycles a 
year) Anovulation is absence of ovulation when it 
would be normally expected (in a post-menarchal, 
premenopausal woman). 
Obesity: 
Obesity is a medical condition in which excess body 
fat has accumulated to the extent   that it may have a 
negative effect on health. People are generally 
considered obese when their body mass index (BMI), a 
measurement obtained by dividing a person's weight by 
the square of the person's height, is over 30 kg/m
2
, with 
the range 25–30 kg/m2 defined as overweight. Some 
East Asian countries use lower values. Obesity increases 
the likelihood of various diseases and conditions, 
particularly cardiovascular diseases, type 2 diabetes, 
obstructive sleep apnea, certain types of cancer, 
osteoarthritis and depression. 
Hirsutism:  
Hirsutism is defined as the presence of terminal coarse 
hairs in females in a male-like distribution. It affects 
around 5-10% of women and is a common presenting 
complaint in the dermatological outpatient department 
(OPD) for cosmetic reasons. It is not only imperative to 
identify the cause of hirsutism but also important to 
know how to recommend the right treatment based on 
the main causative factor. The most important 
determinant in making the diagnosis is a change in the 
form and rate of hair growth. A technique has been 
developed to assess hirsutism with video equipment and 
computer software. Digital imaging of hair development 
is recorded, which demonstrates a significant difference 





Acne is an extremely common skin condition affecting 
more than half of all adolescents and many adults. It is a 
caused by changes in skin structures consisting of hair 
follicle and its associated sebaceous gland via androgen 
stimulation. It is characterized by non inflammatory 
follicular papules or comedones and by inflammatory 
papules, pustules and nodules in its more severe forms. 
Balding: 
 Male like hair loss (in male pattern) in women is known 
as Female pattern hair loss. FPHL is distinctive form of 
hair loss that occurs in women with androgrnetic 
alopecia. Many women are affected by FPHL. In FPHL, 
there is diffuse thinning of hair on the scalp due to 
increased hair shedding or a reduction in hair volume. It 
is normal to lose up to 50-100 hairs a day.
6 
Hyperandrogenism: 
 Hyperandrogenism, also known as androgen excess, is 
a Medical Condition characterized by excessive levels 
of androgens (male sex hormones such as testosterone) 
in the female body and the associated effects of the 
elevated androgen levels. It is an endocrinological 
disorder similar to hyperestrogenism. 
Acanthosis Nigricans: 
Acanthosis nigricans is a fairly common skin 
pigmentation disorder. The most notable sign of 
acanthosis nigricans is dark patches of skin with a thick, 
velvety texture. The affected areas of skin may also itch 
or have an odor. These patches may appear on skin folds 
and other areas, such as the armpits, groin, neck, 
elbows, knees, knuckles, Lips palm, and soles of feet. 
Acanthosis nigricans may be a sign of more serious 




Figure 3: Symptoms of PCOS 
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Hypertension: 
 
Hypertension is usually defined by the presence of a 
chronic elevation of systemic arterial pressure above a 
certain threshold value. However, increasing evidence 
indicates that the cardiovascular (CV) risk associated 
with elevation of blood pressure (BP) above 
approximately 115 ⁄ 75 mm Hg increases in a log-linear 
fashion. 
Dyslipidemia:  
Dyslipidemia are disorders of lipoprotein metabolism, 
including lipoprotein overproduction and deficiency. 
They may manifest as one or more of the following: 
elevated total cholesterol, low-density lipoprotein 
cholesterol (LDL), and triglyceride levels or as 




A complete understanding of the underlying 
Pathophysiology of PCOS is still lacking. Because of the 
heterogeneity of this disorder, there are most likely 
multiple underlying pathophysiologic mechanisms. 
Several theories have been proposed to explain the 
pathogenesis of PCOS. 
1) An alteration in gonadotropin-releasing hormone 
secretion results in increased luteinizing hormone (LH) 
secretion.  
2) An alteration in insulin secretion and insulin action 
results in hyperinsulinemia and insulin resistance. 
3) A defect in androgen synthesis that results in 
increased ovarian androgen production.  
LH Secretion 
LH hyper secretion is a characteristic hallmark of PCOS. 
LH is secreted in a pulsatile manner. Women with PCOS 
have an increase in both the LH pulse frequency and 
amplitude, resulting in increased 24-hour secretion. This 
increase in LH secretion is thought to occur as a result of 
increased frequency of hypothalamic gonadotropin-
releasing hormone (GnRH) pulses. Increased LH, in 
turn, leads to an increase in androgen production by the 
theca cells within the ovary. 
Hyperinsulinemia and Insulin Resistance 
Insulin resistance, defined as reduced glucose response 
to a given amount of insulin, is a characteristic 
metabolic disturbance associated with PCOS. Both 
obese and non obese women with PCOS have a higher 
incidence of insulin resistance and hyperinsulinemia 
than age matched controls; however, obese women with 
PCOS have significantly decreased insulin sensitivity 
compared with non-obese women who have PCOS. 
Insulin resistance is known to precede the development 
of type 2 diabetes mellitus. Studies have shown that 30% 
to 40% of women with PCOS have impaired glucose 
tolerance, and as many as 10% develop type 2 diabetes 
mellitus by the age of 40.
9,10
 Several studies have also 
shown a strong correlation between insulin resistance 
and hyperandrogenism. This association dates back to 
1921, when Achard and Thiers reported on a bearded 
woman who was also a diabetic. Insulin acts 
synergistically with LH to enhance androgen production 
in the ovarian theca cells. Insulin also decreases hepatic 
synthesis and secretion of sex hormone-binding 
globulin, the hormone that binds testosterone in the 
circulation, thus increasing the amount of free 
testosterone that is biologically available.
10 
Women with 
PCOS and hyperinsulinemia typically have elevated free 
testosterone, but the total testosterone concentration may 




The increase in LH, together with hyperinsulinemia, 
leads to an increase in androgen production by ovarian 
theca cells.
10
 The most likely primary factor driving the 
increase in testosterone secretion in PCOS is an increase 
in ovarian enzymatic activity involved in the synthesis 
of testosterone precursors.
12  
TREATMENT FOR PCOS 
Treatment goals should include maintaining a normal 
endometrium, antagonizing the actions of androgens on 
target tissues, reducing insulin resistance (when present), 
and correcting anovulation. The selection of therapy for 
PCOS generally depends on the physical symptoms and 
patients’ desire for childbearing and may be broadly 
categorized into therapy for 
(i) Symptomatic control 
(ii) Fertility management where conception is the 
priority 
(iii) Long-term complications of PCOS.  
For obese women with PCOS, weight loss should be 
considered as a first option. 
Symptomatic Control includes: oral contraceptive pills 
(OCPs), Insulin sensitizing drugs, Drug used in 
treatment of Hirsutism. 
Fertility Management: Ovulation induction: Several 
nonpharmacologic (exercise, diet modifications, and 
weight loss) and pharmacologic (aromatase inhibitors, 
insulin sensitizers, gonadotropins) approaches, used 
alone or in combination, may be used to achieve 
ovulation. 
Table 2: Drug Use for PCOS Treatment 
13,14 




4 Clomiphene citrate 
5 Ethinyl estradiol  
6 Desogestrel 
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Insulin Sensitizing Agents: The safety profile of 
Pioglitazone and rosiglitazone remains to be established, 
hence, Metformin and Clomiphene Citrate must be used 
as the first-choice insulin sensitizing drug. 
Management of Long-term Complications: Lifestyle 
interventions, Management of the metabolic syndrome.
13
 
ALTERNATIVE TREATMENT FOR PCOS 
Alternative medicine has been emerging as one of the 
commonly practiced medicines for different health 
problems. Alternative medicines include many 
modalities, such as kinesiology, herbalism, homeopathy, 
reflexology, acupressure, acupuncture, Ovulation 
induction and massage therapy. Acupuncture is the most 
common modality. The benefit acupuncture seems to 
have for PCOS sufferers is in helping them regulate and 
manage their periods. However, it has also been shown 
to aid in weight loss and reducing headaches as well as 
improving patients’ moods and outlooks. Women with 
PCOS will have needles placed along the acupuncture 
meridians related to the reproductive system. This will 
help stimulate the organs, improve blood flow to the 
area, contribute to normalizing hormone levels, and 
promote the proper functioning of the reproductive 
system. Because it is only in the last 20 years or so that 
acupuncture has started to be widely practiced in the 
West, few studies have been performed on women with 
PCOS receiving acupuncture. In 2000, a study was 
carried out by researchers at Göteborg University in 
Sweden involving 24 women with PCOS who received 
acupuncture for 2–3 months. At the end of the study, 
nine women (38%) had regular ovulation. However, the 
study also found that those women with more severe 
PCOS cases, particularly those participants who had 
high testosterone and insulin levels and were obese, did 
not have any luck with the acupuncture treatment.
15
 In 
Ayurveda Treatment Vamana Karma followed by 
Nastapushpantaka rasa and shatapushpa churna help in 
regularising the menstrual cycle, correcting the secreting 
of luteinising hormone and follicular stimulating 
hormone.
16 
SECONDARY ASSOCIATED DISEASES 
Women with polycystic ovary syndrome (PCOS) are at 
higher risk for several other health conditions, some of 
them serious.
 
 Metabolic Syndrome 
 Prediabetes & type 2 diabetes  
 Weight gain & obesity  
 Cardiovascular Disease  
 Endometrial cancer 
Metabolic syndrome 
Women with PCOS have a higher prevalence of 
'metabolic syndrome. Metabolic syndrome is a 
collection of conditions (listed below) that often occur 
together and increase the risk of type 2 diabetes and 
cardiovascular disease: 
17 
 Impaired glucose tolerance (indicating the 
beginnings of insulin resistance) 
 High blood pressure 
 Abdominal obesity 
 High blood cholesterol 
Prediabetes & type 2 diabetes: 
Women with PCOS have between four and seven times 
increased risk of developing prediabetes and type 2 
diabetes than women without PCOS. Prediabetes is the 
stage before type 2 diabetes. Women with PCOS are 
also more likely to develop diabetes earlier, eg in their 
30s and 40s. This risk is further increased by: 
 being overweight or obese 
 having insulin resistance 
 having an immediate family member with type 2 
diabetes 
Women with PCOS have a higher risk of developing 
diabetes in pregnancy (gestational diabetes). This risk 
increases if you are overweight when pregnant.
18
 
Weight gain & obesity:  
PCOS can occur in women of any weight; however, up 
to 75% of women with PCOS are overweight or obese. 
This excess weight is more likely to be concentrated 
around the abdominal (stomach) region. This gives you 
an 'apple' shape. Women without PCOS tend to be a 
'pear' shape, with weight concentrated around the hips, 
buttocks and thighs. Being overweight, and especially 
having a high amount of abdominal obesity, is 
associated with: 
 A higher risk of insulin resistance (a state where the 
body doesn't use the available insulin effectively to 
help keep the glucose levels stable, ie the insulin 
produced is not working properly) 
 Problems with infertility 
 A higher risk of type 2 diabetes 
 A higher risk of cardiovascular disease, including 
high blood pressure and heart disease 
Cardiovascular disease:  
Women with PCOS are thought to be at higher risk of 
having future heart disease or stroke. There are a number 
of factors that increase the risk of cardiovascular disease 
such as: high blood fats or cholesterol, high levels of 
'bad' cholesterol or low density lipoprotein cholesterol 
which increases the risk of developing heart disease, 
high levels of inflammatory proteins, which can alter the 
function of blood vessels and increase insulin resistance, 
high blood pressure. While being overweight can 
increase these risks, these risks appear to be increased in 




Having the condition PCOS does not cause endometrial 
cancer, rather it is having very infrequent periods which 
may increase the risk of endometrial cancer. Chronic 
anovulation (lack of eggs being released regularly) leads 
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to a lack of menstruation or shedding of the lining of the 
uterus (endometrium). If this happens, the endometrium 
can thicken which can increase the risk of abnormal cells 
that, as a woman ages, can develop into cancerous cells. 
This risk can be greatly reduced with treatments such as 
the oral contraceptive pill. By improving the regularity 
of the menstrual cycle, the uterine lining is shed more 
often during menstruation. Adequate physical activity 
and having a healthy body weight can also assist in 
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